ANDS translation: “We shopped ANA598 to every company who’s even remotely interested in HCV, but there were no takers. WTF do we do now?” Answer: Raise more cash. This deal brings in $11.3M of net proceeds (5.8M sh @$2.15, less the banker’s placement fee): http://finance.yahoo.com/news/Anadys-Pharmaceuticals-Inc-prnews-2488284349.html?x=0&.v=1 Lazard gets paid by ANDS for the direct placement as well as getting paid for the “strategic review.” Nice work if you can get it.